All posts by : chebby

My assigned disease is ANEMIA 

Review the following client scenario: 

Janessa, a 41-year-old female client, presents to the NP complaining of shortness of breath, weakness, and dizziness for “about a month.” She denies having a cough or recent illness. She has a history of endometriosis, and her physical assessment reveals her lungs are clear to auscultation bilaterally, and her mucous membranes are pale.  

 Review your assigned disease process and answer the discussion prompts below with explanation and detail, providing complete references for all citations.   

1. Discuss the underlying pathophysiological mechanisms of your assigned disease process. Which clinical manifestations observed in Janessa’s case could be explained by the pathophysiological mechanisms? 
2. Analyze Janessa’s clinical manifestations in the context of your assigned disease process. Do these findings support a diagnosis of your assigned disease process? Why or why not?  
3. Identify and justify the diagnostic tests (including labs, imaging, or other diagnostic tests) that would be most appropriate for investigating a diagnosis of your assigned disease process in Janessa. What could the results of these tests look like in your assigned disease process? 
4. Compare and contrast your response with a peer who was assigned a different condition. Does their condition fit Janessa’s case? Why or why not? 

• Review the Resources and identify a clinical issue of interest that can form the basis of a clinical inquiry.
• Review the materials offering guidance on using databases, performing keyword searches, and developing PICO(T) questions provided in the Resources.
• Based on the clinical issue of interest and using keywords related to the clinical issue of interest, search at least two different databases in the Walden Library to identify at least four relevant peer-reviewed articles related to your clinical issue of interest. You should not be using systematic reviews for this assignment, select original research articles.
• Review the Resources for guidance and develop a PICO(T) question of interest to you for further study. It is suggested that an Intervention-type PICOT question be developed as these seem to work best for this course. 

• Review the Resources and examine the leadership theories and behaviors introduced.
• Identify two to three scholarly resources, in addition to this Module’s readings, that evaluate the impact of leadership behaviors in creating healthy work environments.
• Reflect on the leadership behaviors presented in the three resources that you selected for review

Describe your clinical experience for this week.

 Must be on Geriatric Patient

• Did you face any challenges, any success? If so, what were they?
• Describe the assessment of a patient, detailing the signs and symptoms (S&S), assessment, plan of care, and at least 3 possible differential diagnosis with rationales.
• Mention the health promotion intervention for this patient.
• What did you learn from this week’s clinical experience that can beneficial for you as an advanced practice nurse?
• Support your plan of care with the current peer-reviewed research guideline.

Submission Instructions:

• Your initial post should be at least 500 words, formatted and cited in current APA style with support from at least 2 academic sources

 One common dilemma faced by psychiatric nurse practitioners is determining who the “client” is. Given that children are typically brought for treatment by their parents, describe how the psychiatric nurse practitioner would respond to a child who discloses they are indulging in illicit behavior and asks you not to tell his or her parents.

 Your initial post should be at least 500 words, formatted, and cited in current APA style with support from at least 2 academic sources. 

Compare the primary care NP role with other APN roles. What are the similarities among the roles, what are the differences, and how would you communicate the role to a healthcare provider and a consumer?

Submission Instructions:

• Your initial post should be at least 500 words, formatted and cited in current APA style with support from at least 2 academic sources. Your initial post is worth 8 points. 

References not older than 6 years

i will have to submit it to turn it in

no chat gbt 

rubric

Discussion Rubric

Discussion Rubric

CriteriaRatingsPts

This criterion is linked to a Learning OutcomeIdentification of Main Issues, Problems, and Concepts

5 ptsDistinguished
Identify and demonstrate a sophisticated understanding of the issues, problems, and concepts.

4 ptsExcellent
Identifies and demonstrate an accomplished understanding of most of issues, problems, and concepts.

2 ptsFair
Identifies and demonstrate an an acceptable understanding of most of issues, problems, and concepts.

1 ptsPoor
Identifies and demonstrate an unacceptable understanding of most of issues, problems, and concepts.

5 pts

This criterion is linked to a Learning OutcomeUse of Citations, Writing Mechanics and APA Formatting Guidelines

3 ptsDistinguished
Effectively uses the literature and other resources to inform their work. Exceptional use of citations and extended referencing. High level of APA precision and free of grammar and spelling errors.

2 ptsExcellent
Effectively uses the literature and other resources to inform their work. Moderate use of citations and extended referencing. Moderate level of APA precision and free of grammar and spelling errors.

1 ptsFair
Ineffectively uses the literature and other resources to inform their work. Moderate use of citations and extended referencing. APA style and writing mechanics need more precision and attention to detail.

0 ptsPoor
Ineffectively uses the literature and other resources to inform their work. An unacceptable use of citations and extended referencing. APA style and writing mechanics need serious attention.

3 pts

This criterion is linked to a Learning OutcomeResponse to Posts of Peers

2 ptsDistinguished
Student constructively responded to two other posts and either extended, expanded or provided a rebuttal to each.

1 ptsFair
Student constructively responded to one other post and either extended, expanded or provided a rebuttal.

0 ptsPoor
Student provided no response to a peer’s post.

2 pts

Total Points: 10

Please ensure that the Discussion includes more than 200 words with scholarly articles, and the plagiarism level must remain below 20%.

Mounjaro vs Ozempic: A Guide to Two Endocrine Disorder Treatments

Well-established pharmacological agents have made considerable advances in treating endocrine disorders, precisely type 2 diabetes mellitus (T2DM) and obesity. Newer agents, such as Mounjaro (tirzepatide) and Ozempic (semaglutide), are well-known for their blood sugar-regulating and weight loss-promoting effects. Both agents are incretin-based therapies but have unique pharmacological profiles that affect their clinical use.

Similarities

Mounjaro and Ozempic have many similarities, including their mechanism of action and therapeutic benefits. Both agents, as incretin mimetics, act on the glucagon-like peptide-1 (GLP-1) receptor to increase insulin release, decrease glucagon secretion, and delay gastric emptying, ultimately resulting in better control of blood sugar levels. (Jastreboff et al., 2022). Furthermore, both Exenatide and Semaglutide are injected subcutaneously and have demonstrated clinically meaningful weight loss in people with T2DM and obesity (Garber, 2022). These similarities underline their potential for aiding in ameliorating blood glucose levels and the more general metabolic derangements accompanying obesity and diabetes.

Differences

While they have similarities, Mounjaro and Ozempic vary in some important ways. Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist, while Ozempic (semaglutide) is a specific GLP-1 receptor agonist (Frías et al., 2021). Mounjaro’s extra GIP receptor activity provides better insulin secretion and potential additional weight loss benefits than Ozempic. Clinical trials have indicated that tirzepatide may significantly reduce HbA1c and body weight more than semaglutide (Jastreboff et al., 2022). Additionally, there are also differences in dosing; Ozempic is started at a lower dose (0.25 mg weekly) and titrated to a maximum of 2 mg weekly, while Mounjaro is available in a range of doses (2.5 mg to 15 mg weekly) to suit different patient needs (Garber, 2022).

Clinical Implications

Introducing Mounjaro and Ozempic is initiating a new phase in T2DM and obesity management. The improved weight loss and glycemic control with Mounjaro could translate into preferential usage in patients needing more robust metabolic agents. However, healthcare providers need to consider cost, willingness to take medication, and risk of complications such as gastrointestinal disturbance for proper therapy. More studies are necessary on these agents’ long-term safety and cardiovascular impact.

Conclusion

Mounjaro and Ozempic are valuable agents in the pharmacologic management of diabetes and obesity, respectively; because these medications have different mechanisms of action and clinical effects, individualized treatment decisions are needed to provide the best possible patient results.

References

Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., & Liu, B. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. https://doi.org/10.1056/NEJMoa2107519

Garber, A. J. (2022). Incretin-based therapies in managing type 2 diabetes: Role of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists. Diabetes Care, 45(Suppl 1), S219-S227. https://doi.org/10.2337/dc21-S014

Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Sturm, K., & Hompesch, M. (2022). Effects of tirzepatide on body weight in people with obesity: A phase 3 trial. New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038

Semaglutide vs Trizepatide. https://www.premieraestheticsva.com/post/semaglutide-vs-trizepatide

Please ensure that the Discussion includes more than 200 words with scholarly articles, and the plagiarism level must remain below 20%.

For the treatment of diabetes mellitus (DM) type 2 and obesity the pharmacology has noted significant advances in these fields. There are two new medications to come on the endocrinology scenario that are called Mounjaro (tripeptide) and Ozempic (semaglutide) because of their efficacy in these conditions DM type 2 and obesity. Both drugs are glucagon-like peptide 1 (GLP-1) receptor agonists, which imitate the natural GLP-1 hormone that helps to control the blood sugar and appetite. Like drugs, they have detailed differences: their mechanisms of action and the variety of conditions they treat will have clinical implications for their use in endocrine disorders. An important similarity between Mounjaro and Ozempic is that they act on the GLP-1 receptor, which helps regulate insulin liberation and glucagon release in response to food intake. This is about better blood sugar control. Thus, these are highly effective in treating type 2 diabetes (Latif et al., 2021). Moreover, both drugs help in weight loss, which is a key of the managing obesity frequently associated with type 2 diabetes. Clinical investigation of these two medications have shown that they guide the substantial decreases in HbA1c (a marker of long-term blood sugar control) and body weight and, therefore, are beautiful treatment options for patients with both conditions.

However, the principal difference with the Mounjaro and Ozempic is how they work. Mounjaro, in the manuscript, was described as a doble agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor (Zheng et al., 2024). Another hormone that regulates insulin and glucose metabolism is Mounjaro, and it has the added capacity to target both GLP-1 and GIP receptors, expanding its potential effect on reducing blood sugar and weighing down on our overall body weight more than a single GLP1 receptor agonist like Ozempic. Its enhanced signal is expected to guide to more effective treatment options for type 2 diabetes and maturity-related conditions.

There are many clinical implications and differences for healthcare providers using Mounjaro or Ozempic for the patients. Compared to other options, Mounjaro is more likely to be better for someone with more extreme type 2 diabetes or obesity because it has higher efficacy when it comes to both lowering blood sugar and weight loss (Zheng et al., 2024). While Ozempic is generally better studied, it has a better safety and efficacy profile, which you may prefer over the GLP 1 receptor agonists in patients who do well with them or patients who require a more well-studied medication. Both drugs can cause gastrointestinal problems, but Mounjaro’s dual activity might carry a very slightly higher chance of problems. Consequently, these medications will be compared, and finally, the choice will be made based on the patient’s characteristics (response and tolerance to the possible side effects of treatment and the severity of the condition).

Mounjaro and Ozempic are both efficacious, but both hold potential clinical complications. The risk of pancreatitis inflammation of the pancreas is one primary concern because GLP-1 receptor agonists have been associated with pancreatitis (Ayoub et al., 2025). Patients with pancreatitis background should be provided these drugs, and they should be closely monitored. In fact, another gastrointestinal symptom such nausea, vomiting, and diarrhea are very frequent, and some patients have more serious side effects that make difficult for patient to follow the treatment. Compared to Ozempic, Mounjaro’s dual action might make stomach pain more likely.

References

‌ Ayoub, M., Chela, H., Amin, N., Hunter, R., Anwar, J., Tahan, V., & Daglilar, E. (2025). Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis. Journal of Clinical Medicine, 14(3), 944. https://doi.org/10.3390/jcm14030944

Latif, W., Lambrinos, K. J., & Rodriguez, R. (2021). Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs). https://www.ncbi.nlm.nih.gov/books/NBK572151/

Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024). Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy, 9(1), 234. https://www.nature.com/articles/s41392-024-01931-z

Hematopoietic:
J.D. is a 37 years old white woman who presents to her gynecologist complaining of a 2-month history of intermenstrual bleeding, menorrhagia, increased urinary frequency, mild incontinence, extreme fatigue, and weakness. Her menstrual period occurs every 28 days and lately there have been 6 days of heavy flow and cramping. She denies abdominal distension, back-ache, and constipation. She has not had her usual energy levels since before her last pregnancy.

Past Medical History (PMH):
Upon reviewing her past medical history, the gynecologist notes that her patient is a G5P5with four pregnancies within four years, the last infant having been delivered vaginally four months ago. All five pregnancies were unremarkable and without delivery complications. All infants were born healthy. Patient history also reveals a 3-year history of osteoarthritis in the left knee, probably the result of sustaining significant trauma to her knee in an MVA when she was 9 years old. When asked what OTC medications she is currently taking for her pain and for how long she has been taking them, she reveals that she started taking ibuprofen, three tablets each day, about 2.5 years ago for her left knee. Due to a slowly progressive increase in pain and a loss of adequate relief with three tablets, she doubled the daily dose of ibuprofen. Upon the recommendation from her nurse practitioner and because long-term ibuprofen use can cause peptic ulcers, she began taking OTC omeprazole on a regular basis to prevent gastrointestinal bleeding. Patient history also reveals a 3-year history of HTN for which she is now being treated with a diuretic and a centrally acting antihypertensive drug. She has had no previous surgeries.

Case Study Questions

1. Name the contributing factors on J.D that might put her at risk to develop iron deficiency anemia.
2. Within the case study, describe the reasons why J.D. might be presenting constipation and or dehydration.
3. Why Vitamin B12 and folic acid are important on the erythropoiesis? What abnormalities their deficiency might cause on the red blood cells?
4. The gynecologist is suspecting that J.D. might be experiencing iron deficiency anemia.
   In order to support the diagnosis, list and describe the clinical symptoms that J.D. might have positive for Iron deficiency anemia.
5. If the patient is diagnosed with iron deficiency anemia, what do you expect to find as signs of this type of anemia? List and describe.
6. Labs results came back for the patient. Hb 10.2 g/dL; Hct 30.8%; Ferritin 9 ng/dL; red blood cells are smaller and paler in color than normal. Research list and describe for appropriate recommendations and treatments for J.D.

Cardiovascular
Mr. W.G. is a 53-year-old white man who began to experience chest discomfort while playing tennis with a friend. At first, he attributed his discomfort to the heat and having had a large breakfast. Gradually, however, discomfort intensified to a crushing sensation in the sternal area and the pain seemed to spread upward into his neck and lower jaw. The nature of the pain did not seem to change with deep breathing. When Mr. G. complained of feeling nauseated and began rubbing his chest, his tennis partner was concerned that his friend was having a heart attack and called 911 on his cell phone. The patient was transported to the ED of the nearest hospital and arrived within 30 minutes of the onset of chest pain. In route to the hospital, the patient was placed on nasal cannula and an IV D5W was started. Mr. G. received aspirin (325 mg po) and 2 mg/IV morphine. He is allergic to meperidine (rash). His pain has eased slightly in the last 15 minutes but is still significant; was 9/10 in severity; now7/10. In the ED, chest pain was not relieved by 3 SL NTG tablets. He denies chills.

Case Study Questions

1. For patients at risk of developing coronary artery disease and patients diagnosed with acute myocardial infarct, describe the modifiable and non-modifiable risk factors.
2. What would you expect to see on Mr. W.G. EKG and which findings described on the case are compatible with the acute coronary event?
3. Having only the opportunity to choose one laboratory test to confirm the acute myocardial infarct, which would be the most specific laboratory test you would choose and why?
4. How do you explain that Mr. W.G temperature has increased after his Myocardial Infarct, when that can be observed and for how long? Base your answer on the pathophysiology of the event.
5. Explain to Mr. W.G. why he was experiencing pain during his Myocardial Infarct. Elaborate and support your answer.

Submission Instructions:

• Include both case studies in your post.
• Your initial post should be at least 500 words, formatted and cited in current APA style with support from at least 2 academic sources. Your initial post is worth 8 points.

Rubric 

Discussion Rubric

Discussion Rubric

CriteriaRatingsPts

This criterion is linked to a Learning OutcomeIdentification of Main Issues, Problems, and Concepts

5 to >4.0 ptsDistinguished
Identifies and demonstrates a sophisticated understanding of the issues, problems, and concepts.

4 to >3.0 ptsExcellent
Identifies and demonstrates an accomplished understanding of most issues, problems, and concepts.

3 to >0.0 ptsFair
Identifies and demonstrates an acceptable understanding of most issues, problems, and concepts.

0 ptsPoor
Identifies and demonstrates an unacceptable understanding of most issues, problems, and concepts. Or nothing was posted.

5 pts

This criterion is linked to a Learning OutcomeUse of Citations, Writing Mechanics and APA Formatting Guidelines

3 ptsDistinguished
Effectively uses the literature and other resources to inform their work. Exceptional use of citations and extended referencing. High level of APA precision and free of grammar and spelling errors.

2 ptsExcellent
Effectively uses the literature and other resources to inform their work. Moderate use of citations and extended referencing. Moderate level of APA precision and free of grammar and spelling errors.

1 ptsFair
Ineffectively uses the literature and other resources to inform their work. Moderate use of citations and extended referencing. APA style and writing mechanics need more precision and attention to detail.

0 ptsPoor
Ineffectively uses the literature and other resources to inform their work. Unacceptable use of citations and extended referencing. APA style and writing mechanics need serious attention. Or nothing was posted.

3 pts

This criterion is linked to a Learning OutcomeResponse to Posts of Peers

2 ptsDistinguished
Student constructively responded to two other posts and either extended, expanded or provided a rebuttal to each.

1 ptsFair
Student constructively responded to one other post and either extended, expanded or provided a rebuttal.

0 ptsPoor
Student provided no response to a peer’s post.

2 pts

Total Points: 1

APA format

references no less than 6 years old

will be check through turn it in